Pharmaceutical News

RSS

Researchers identify molecule that can stop the formation of amyloid fibrils

A molecule which can stop the formation of long protein strands, known as amyloid fibrils, that cause joint pain in kidney dialysis patients has been identified by researchers at the University of Leeds.

29 Aug 2011

Pfizer receives FDA approval for XALKORI capsules to treat ALK-positive NSCLC

Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved XALKORI (crizotinib) capsules, the first-ever therapy targeting anaplastic lymphoma kinase (ALK), for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is ALK-positive as detected by an FDA-approved test.

29 Aug 2011

Nurofen mix up with Seroquel schizophrenia drug warns MHRA

British drug regulators have issued a safety alert on Thursday after discovering packs of the over-the-counter painkiller Nurofen Plus containing the anti-psychotic drug Seroquel XL.

26 Aug 2011

Autism link to vaccines dispelled by a large review of studies

According to a report issued by the US Institute of Medicine (IOM), vaccines are largely safe, and do not cause autism or diabetes. This conclusion followed a review of more than 1,000 published research studies.

26 Aug 2011

Rotavirus vaccine still effective in reducing diarrhea-related deaths in Mexico, researchers say

"The rotavirus vaccine introduced in Mexico in 2007 still appears to be preventing diarrhea-related deaths in children, despite speculation that years later the vaccine may not be as effective," according to the Los Angeles Times' "Booster Shots" blog.

26 Aug 2011

Viewpoints: Drug shortages = rationing; Changing forces in health marketplace; Birth control mandate

A widespread shortage of prescription drugs is hampering the treatment of patients who have cancer, severe infections and other serious illnesses. While some Republican politicians have railed against the imaginary threat of rationing under health care reform, Congress has done nothing to alleviate the all-too-real rationing of lifesaving drugs caused by this crisis.

26 Aug 2011

IOM report: Few health problems are clearly associated with vaccines

An analysis of more than 1,000 research articles concluded that few health problems are caused by or clearly associated with vaccines.

26 Aug 2011

Yale scientists synthesize huperzine A to combat Alzheimer's

Scientists at Yale University have developed the first practical method to create a compound called huperzine A in the lab.

26 Aug 2011

Google pays $500 million settlement in pharmacy ad probe

With the settlement, the Internet search engine will not face criminal prosecution related to accusations that it improperly benefited from ads promoting Canadian pharmacies that illegally imported medicines into the United States.

26 Aug 2011

Neoadjuvant chemotherapy prior to surgery can benefit women with lobular breast cancer

Researchers at the Medical University of Vienna have found that the breast of one in two women with lobular breast cancer can be preserved through chemotherapy prior to a breast operation.

26 Aug 2011

Researchers develop single vaccines to prevent rabies, Ebola infection

Researchers from Thomas Jefferson University, among other institutions, including the National Institute of Allergy and Infectious Diseases, have developed single vaccines to protect against both rabies and the Ebola virus.

26 Aug 2011

IOM issues new report on evidence and causality of vaccine harms

The Institute of Medicine's Panel on Adverse Effects of Vaccines issued a report today on the evidence and causality of vaccine harms. Despite a glowing press release, the report does little to allay public concerns over adverse effects of vaccines and suggests that we urgently need more science on vaccine adverse effects.

26 Aug 2011

Firazyr receives FDA approval for treatment of HAE acute attacks

The U.S. Food and Drug Administration today approved Firazyr (icatibant) Injection for the treatment of acute attacks of a rare condition called hereditary angioedema (HAE) in people ages 18 years and older.

26 Aug 2011

Boehringer Ingelheim, Lilly receive EU approval for linagliptin to treat type 2 diabetes

Boehringer Ingelheim and Eli Lilly and Company today received Marketing Authorization from the European Commission for linagliptin 5 mg film-coated tablets for the treatment of adults with type 2 diabetes.

26 Aug 2011

Shire receives FDA marketing approval for FIRAZYR to treat acute attacks of HAE

Shire plc, the global specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for FIRAZYR for treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.

26 Aug 2011

Antidepressant alert – Citalopram associated to heart rhythm disturbances

Antidepressant citalopram (Celexa, Forest Laboratories) should not be used in doses higher than 40 mg per day because of concerns that it can cause potentially fatal changes in heart rhythm, the US Food and Drug Administration (FDA) warns.

25 Aug 2011

Allergan gets FDA nod for use of Botox in urinary incontinence

Allergan Inc. has received United States Food and Drug Administration (FDA) approval to market the wrinkle smoother Botox as a treatment for urinary incontinence. The FDA approved the drug for people with overactive bladders who have neurologic conditions such as multiple sclerosis and spinal cord injuries, the agency said today in a statement. The medicine is injected into the bladder to increase its capacity by relaxing muscles.

25 Aug 2011

Simcere receives Chinese SFDA approval for Iremod to treat active rheumatoid arthritis

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it has received the new drug approval from the State Food and Drug Administration for Iremod.

25 Aug 2011

Removal of OTC drugs for toddlers from the market reduces therapeutic errors

A new study by researchers at the University of Maryland has revealed a 46 percent drop in reported errors after drugmakers in October 2007 removed from the market a number of over-the-counter cough and cold medications labeled for children under the age of 2.

25 Aug 2011

AHF shares The Lancet's concerns over use of Gilead's Truvada as HIV prevention pill

Today AIDS Healthcare Foundation (AHF) commented on an editorial published in the September 2011 issue of The Lancet Infectious Diseases that raises concerns about the use of the HIV treatment drug Truvada, manufactured by Gilead Sciences Inc., as an HIV prevention pill or pre-exposure prophylaxis (PrEP), agreeing with the publication's public health concerns.

25 Aug 2011